close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

9.970 +1.210 (+13.81%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
$15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying ↗
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
The Latest Analyst Ratings for Day One Biopharmaceutical ↗
 
Via Benzinga
News headline image
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Where Day One Biopharmaceutical Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Ratings for Day One Biopharmaceutical ↗
 
Via Benzinga
News headline image
Why Day One Biopharmaceuticals Stock Is Trading Higher Premarket Today ↗
 
Via Benzinga
News headline image
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
$3.6 Bet On Asana? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
News headline image
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review ↗
The Nasdaq held near 52-week highs while small caps ramped up. 
Via Investor's Business Daily
News headline image
7 Analysts Have This to Say About Day One Biopharmaceutical ↗
 
Via Benzinga
News headline image
Day One Announces Pricing of Public Offering of Common Stock
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Proposed Public Offering of Common Stock
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Shares of Day One Pharmaceuticals Are Up Monday ↗
The clinical-stage biotech released early trial news regarding its lead therapy candidate. 
Via The Motley Fool
News headline image
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding. 
Via Benzinga
News headline image
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes ↗
ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Mallinckrodt Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket ↗
Gainers Forza X1, Inc. (NASDAQ: FRZA) shares rose 85.6% to $2.32 in pre-market trading after the company tweeted Friday 'Get ready for something extraordinary! Stay tuned!' 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start the week off right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
News headline image
Day One Biopharmaceuticals, ImmunoGen And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today